Evidence map›Paper›PMID 39936765›Full record

ArticleRevista peruana de medicina experimental y salud publica2025

Development of the antigenic recombinant tropomyosin of Echinococcus granulosus in a bacterial system as a vaccinal candidate against canine echinococcosis.

Janet Acosta-Benites, Luis M Jara, Manuela Verastegui Pimentel, Pepe M Obregón Maldonado, Faride Altamirano-Zevallos, Nicasio Valencia Mamani, Cesar M Gavidia

Abstract read
In one paragraph

Article in Revista peruana de medicina experimental y salud publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Janet Acosta-BenitesFacultad de Farmacia y Bioquímica, Universidad Nacional Mayor de San Marcos, Lima, Perú.ORCID http://orcid.org/0009-0001-8509-5752
Luis M JaraFacultad de Medicina Veterinaria y Zootecnia, Universidad Peruana Cayetano Heredia, Lima, Perú.ORCID http://orcid.org/0000-0002-8770-5657
Manuela Verastegui PimentelLaboratorio de Investigación de Enfermedades Infecciosas (LIEI), Facultad de Ciencia y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú.ORCID http://orcid.org/0000-0002-7500-1353
Pepe M Obregón MaldonadoLaboratorio de Investigación de Enfermedades Infecciosas (LIEI), Facultad de Ciencia y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú.ORCID http://orcid.org/0000-0002-2322-6091
Faride Altamirano-ZevallosFacultad de Medicina Veterinaria, Universidad Nacional Mayor de San Marcos, Lima, Perú.ORCID http://orcid.org/0000-0003-4348-8571
Nicasio Valencia MamaniFacultad de Ciencias e Ingeniería, Universidad Nacional de Huancavelica, Huancavelica, Perú.ORCID http://orcid.org/0000-0002-9408-7770
Cesar M GavidiaFacultad de Medicina Veterinaria, Universidad Nacional Mayor de San Marcos, Lima, Perú.ORCID http://orcid.org/0000-0003-3936-5077

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motivation for the study. Cystic echinococcosis is a neglected disease associated with contact between dogs, humans and sheep. In countries such as Peru, control programs include vaccination of sheep; however, vaccination in dogs is a late control strategy to eliminate the adult parasite or to avoid infection with eggs in the environment. Main findings. We were able to clone and express a recombinant protein (tropomyosin) of the adult parasite in a bacterial system with immunogenic properties. Implications. Obtaining the tropomyosin recombinant protein from E. granulosus allows the development of vaccine candidates in dogs and the exploration of diagnostic tests in hosts. This study aimed to clone, express and produce the recombinant Echinococcus granulosus tropomyosin isoform A protein (EgTrpA) that maintains its antigenic and immunogenic properties as a potential vaccine candidate for dogs and sheep. The Echinococcus granulosus tropomyosin protein (EgTrp) gene was cloned into two vectors: Tropo/His-tag [pET28a (+)] and Tropo/GST-tag (pGEX6P-1). It was then expressed in E. coli BL21. Protein identity was determined by two-dimensional electrophoresis. Immunogenicity and antigenicity were verified by immunizing rabbits with each recombinant protein and assessed by western blot and ELISA. Two-dimensional electrophoresis identified the recombinant EgTrp protein as isoform A. The recombinant proteins showed recognition reactions on Western Blot and serum from immunized rabbits showed an increase in Tropo/His-tag IgG antibodies similar to Tropo/GST-tag. The recombinant EgTrpA protein showed antigenic and immunogenic characteristics in laboratory animals.

Indexed as

Antigens, HelminthDog DiseasesEchinococcosisEchinococcus granulosusTropomyosinAnimalsDogsRabbitsRecombinant ProteinsVaccinationVaccine DevelopmentAntigens, HelminthRecombinant ProteinsTropomyosin

Identifiers

PMID39936765
PMCPMC11797582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.